*PLEASE READ!!*

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

In response to customer requests, Helena is pleased to provide the text for procedural package inserts in a digital format editable for your use. The text for the procedure you requested begins on page three of this document. Helena procedures contain the content outlined in the NCCLS (GP2-A#) format, except in the order sequence required by FDA regulations. As the NCCLS format is a guideline, you may retain these procedures as developed by the manufacturer (adding your title/authorization page) or manipulate the text file to produce your own document, matching the NCCLS section order exactly, if preferred.

We also provide the procedure in an Adobe Acrobat PDF format for download at www.helena.com as a “MASTER” file copy. Below are the specifications and requirements for using these digital files. Following the specifications is the procedure major heading sequence as given in the FDA style. Where there is a difference in order, or other notation in the outline, this will be indicated in braces { }.

WHAT YOU NEED TO KNOW:

1) These files represent the most current revision level to date. Your current product inventory could contain a previous revision level of this procedure.

2) The Microsoft Word document provides the text only from the master procedure, in a single-column format.

- It may not contain any illustrations, graphics or captions that may be part of the master procedure included in the kit.

- The master procedure may have contained special formatting characters, such as subscripts, superscripts, degree symbols, mean symbols and Greek characters such as alpha, beta, gamma, etc. These symbols may or may not display properly on your desktop.

- The master procedures may also contain columns of tabbed data. Tab settings may or may not be displayed properly on your desktop.

3) The Adobe Acrobat PDF file provides a snapshot of the master procedure in a printable 8.5 x 11” format. It is provided to serve as a reference for accuracy.

4) By downloading this procedure, your institution is assuming responsibility for modification and usage.

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

HELENA LABORATORIES LABELING – Style/Format Outline

1) PRODUCT {Test} NAME

2) INTENDED USE and TEST TYPE (qualitative or qualitative)

3) SUMMARY AND EXPLANATION

4) PRINCIPLES OF THE PROCEDURE

{NCCLS lists SAMPLE COLLECTION/HANDLING next}

5) REAGENTS (name/concentration; warnings/precautions; preparation; storage; environment; Purification/treatment; indications of instability)

6) INSTRUMENTS required – Refer to Operator Manual (... for equipment for; use or function; Installation; Principles of operation; performance; Operating Instructions; Calibration\* {\*is next in order for NCCLS – also listed in “PROCEDURE”}’ precautions/limitations/hazards; Service and maintenance information

7) SAMPLE COLLECTION/HANDLING

8) PROCEDURE

{NCCLS lists QUALITY CONTROL (QC) next}

9) RESULTS (calculations, as applicable; etc.)

10) LIMITATIONS/NOTES/INTERFERENCES

11) EXPECTED VALUES

12) PERFORMANCE CHARACTERISTCS

13) BIBLIOGRAPHY (of pertinent references)

14) NAME AND PLACE OF BUSINESS OF MANUFACTURER

15) DATE OF ISSUANCE OF LABELING (instructions)

For Sales, Technical and Order Information, and Service Assistance,   
call Helena Laboratories toll free at 1-800-231-5663.

Form 364

Helena Laboratories

1/2006 (Rev 3)

SPIFE® Nexus   
Alkaline Hemoglobin Procedure

Cat. No. 2415

**INTENDED USE**

The SPIFE Nexus Alkaline Hemoglobin method is intended for the qualitative and semi-quantitative determination of hemoglobins using agarose electrophoresis in alkaline buffer on the SPIFE Nexus system. The system is used as a screening method for in-vitro diagnostic use.

For In-Vitro Diagnostic Use.

Rx Only.

**SUMMARY**

Hemoglobins (Hb) are a group of proteins whose chief functions are to transport oxygen from the lungs to the tissues and carbon dioxide in the reverse direction. They are composed of polypeptide chains, called globin, and iron protoporphyrin heme groups. A specific sequence of amino acids constitutes each of four polypeptide chains. Each normal hemoglobin molecule contains one pair of alpha and one pair of non-alpha chains. The non-alpha chains of fetal hemoglobin are called gamma. A minor (3%) hemoglobin fraction called HbA2 contains alpha and delta chains. Two other chains are formed in the embryo.

The major hemoglobin in the erythrocytes of the normal adult is HbA, but there are small amounts of HbA2 and HbF. In addition, over 400 mutant hemoglobins are now known, some of which may cause serious clinical effects, especially in the homozygous state or in combination with another abnormal hemoglobin. Wintrobe1 divides the abnormalities of hemoglobin synthesis into three groups:

(1) Production of an abnormal protein molecule (e.g. sickle cell anemia)

(2) Reduction in the amount of normal protein synthesis (e.g. thalassemia

(3) Developmental anomalies (e.g. hereditary persistence of fetal hemoglobin (HPFH)

The two mutant hemoglobins most commonly seen in the United States are HbS and HbC. Hb Lepore, HbE, HbG-Philadelphia, HbD-Los Angeles and HbO-Arab may be seen less frequently.2

Gel Electrophoresis is routinely used for separating and identifying hemoglobinopathies. The protocol for hemoglobin electrophoresis involves stepwise use of two systems.3-8 Initial electrophoresis testing is performed in an alkaline buffer system, followed by further typing using acid buffers, which measures a property other than electrical charge. Historically, cellulose acetate with alkaline buffers was used to rapidly separate HbA, F, S and C and other variants. Further testing using citrate agar with acid buffers was used to differentiate between variants with similar electrophoresis properties. This testing can now be performed using acid and alkaline buffers on agarose gel with greater automation.

This method is based on the complex interactions of hemoglobin with an alkaline electrophoretic buffer and agarose support media. The SPIFE Nexus Alkaline Hemoglobin method is a simple procedure requiring minute quantities of hemolysate to provide a screening method for the presence of abnormal hemoglobins such as HbS, HbC and HbF.

**PRINCIPLE**

Very small samples of hemolysates prepared from washed, packed cells are automatically applied to the SPIFE Nexus Alkaline Hb gel. The hemoglobins in the sample are separated by electrophoresis using an alkaline buffer and are stained with Acid Blue Stain.

**REAGENTS**

**1. SPIFE Alkaline Hb Gel**

**Ingredients:** Each gel contains agarose in tris glycine buffer with 0.05% EDTA and sodium azide as a preservative. **WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY.** To prevent the formation of toxic vapors, sodium azide should not be mixed with acidic solutions. When discarding reagents containing sodium azide, always flush sink with copious quantities of water. This will prevent the formation of metallic azides which, when highly concentrated in metal, are potentially explosive. In addition to purging with water, plumbing should occasionally be decontaminated with 10% NaOH. **Preparation for Use:** The gels are ready for use as packaged.  **Storage and Stability:** The gels should be stored horizontally at room temperature (15 to 30°C) and are stable until the expiration date indicated on the package. The gels must be stored in the protective packaging in which they are shipped. **DO NOT REFRIGERATE OR FREEZE THE GELS.**  **Signs of Deterioration:** Any of the following conditions may indicate deterioration of the gel: (1) crystalline appearance indicating the agarose has been frozen, (2) cracking and peeling indicating drying of the agarose, (3) bacterial growth indicating contamination, (4) thinning of the gel blocks.

**2. SPIFE Nexus Blue   
Ingredients:** The stain contains 0.5% (w/v) acid blue stain, 5% acetic acid and surfactant.  **WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.   
Preparation for Use:** The stain is ready for use as packaged.  **Storage and Stability:** Stable for one year stored at 15 to 30°C in a closed container.  **Signs of Deterioration:** The prepared stain should be a homogeneous mixture free of precipitate. Discard if precipitate forms.

**3. Hemolysate Reagent   
Ingredients:** The reagent contains deionized water with 0.005 M EDTA, 0.175% saponin and 0.07% potassium cyanide.  **WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT PIPETTE BY MOUTH.** The reagent contains potassium cyanide.  **Preparation for Use:** The reagent is ready for use as packaged.  **Storage and Stability:** The reagent should be stored at room temperature (15 to 30°C) and is stable until the expiration date indicated on the vial.  **Signs of Deterioration:** Discard if solution has precipates or flocculent.

**4. Citric Acid Destain   
Ingredients:** After dissolution, the destain contains 0.3% (w/v) citric acid.  **WARNING: FOR IN-VITRO DIAGNOSTIC USE. DO NOT INGEST - IRRITANT.   
Preparation for Use:** Pour 11 L of deionized water into the Destain vat. Add the entire package of Destain. Mix well until completely dissolved.  **Storage and Stability:** Store the Destain at 15 to 30°C. It is stable until the expiration date on the package.  **Signs of Deterioration:** Discard if solution becomes cloudy.

**INSTRUMENT**

A SPIFE Nexus analyzer must be used to apply samples, electrophorese, stain, destain, dry and then scan the gels. The gels may be scanned on a separate densitometer such as the QuickScan Touch Plus (Cat. No. 1640). Refer to the Operator’s Manual for detailed instructions.

**SPECIMEN COLLECTION AND HANDLING**

**Specimen:** Whole blood collected in EDTA tubes is the specimen of choice.

**Specimen Storage:** If storage is necessary, whole blood and packed cells may be stored up to 1 week at 2 to 8°C. Frozen samples may produce an artifact band anodal to HbA.

**Specimen Preparation:** Washed, packed cell hemolysates must be prepared for each patient specimen.

A) Whole Blood sample

1. Centrifuge anticoagulated blood for 10 minutes to separate cells from plasma.

2. Remove plasma.

3. Wash packed cells 3 times by resuspending in 5 to 10 volumes of normal saline solution (0.85% NaCl), centrifuging and aspirating supernatant.

4. After washing the samples, prepare the hemolysates by mixing 10 µL sample to 100 µL Hemolysate Reagent. Vortex or shake vigorously for 15 seconds.

B) Control   
AFSC (Cat. No. 5331) 1:2 (1 part control + 1 part Hemolysate Reagent)

**PROCEDURE**

**Materials provided:** The following materials needed for the procedure are contained in the SPIFE Nexus Alkaline Hemoglobin Kit (Cat. No. 2415). Individual items are not available.

SPIFE Alkaline Hemoglobin Gels (10)

SPIFE Nexus Blue (1 vial)

Hemolysate Reagent (2 bottles)

Citric Acid Destain (2 pkgs)

REP Blotter C (10)

Serrated Blade Applicator Kit, 20 Sample (10)

**Materials available but not contained in the kit:**

**ITEM CAT. NO.**

SPIFE Nexus Analyzer 1650

QuickScan Touch Plus 1640

Gel Block Remover 1115

AFSC Hemo Control 5331

SPIFE Dispo Sample Cups 3369

SPIFE 20,40,60 Dispo Cup Tray 3370

SPIFE Nexus Cassette 2580

SPIFE Nexus Applicator Templates 2570

SPIFE Nexus Applicator Blade Weights 2572

SPIFE Nexus Dispo Stain Cups 2575

Pos ID Barcode Labels for Touch and

SPIFE Nexus Systems 1696

Rep Prep 3100

SPIFE Nexus Reagent Roller 2583

SPIFE Nexus Ready Run Kit 2582

SPIFE Nexus Carbon Electrode Insert 2576

**Materials needed but not provided:**

0.85% saline

**STEP BY STEP METHOD**

**I. Sample Preparation**A. Prepare lysates of patient specimens and controls as instructed in the "Specimen Preparation" section.

B. Slide the Disposable Sample Cup strip into the top channel of the Cup Tray (numbered 1 to 20).

C. Pipette 17 µL of patient or control lysate into each of the Disposable Cups. Cover until ready for use.

**II. SPIFE Nexus Preparation**

A. Fill designated bottles with 0.85% saline, deionized water, and destain.

B. Turn on the SPIFE Nexus. Click on the SPIFE Nexus icon to initialize.

C. If this is the first test of the day, prime the instrument according to the instructions in the SPIFE Nexus Operator’s Manual.

D. Open the main door of the instrument and prepare the items onboard the instrument.

1. Ensure that the following items are in their respective onboard storage locations: **Platen Cover** with the Carbon Electrode Insert and **Dryer Cover** with the red sticker toward the back of the instrument.

2. Place the prepared **Sample Cup Tray** onto the sample tray platform. Be sure to fully insert the sample tray.

3. **Stain/Reagent Dispenser**

a. Fill three Stain Cups each with 700 µL of SPIFE Nexus Blue stain and place a Stain Cup in each slot of the Stain/Reagent Dispenser.

b. Place a clean Reagent Roller bar between the hooks on the Stain/Reagent Dispenser.

4. **Consumables Tray**

a. Slide the Consumables Tray forward from its home position.

b. Prepare the Applicator Holder

(1) Place an Alkaline HB Applicator Blade Template on top of the Applicator Holder.

(2) Place an Applicator Blade in the designated slot corresponding to the sample cups loaded within the sample tray. **NOTE: The Applicator Blades will only fit into the slots in the Applicator Holder one way; do not try to force the Applicator Blades into the slots.**

(3) Place the Applicator Blade Weight on top of the Applicator Blade with the thick side facing the front of the instrument.

c. Slide the Consumables Tray into position in the back of the instrument.

5.  **Gel Cassette**

a. Place the bottom half of the Gel Cassette on the electrophoresis platen with the two pins lined up on the left side.

b. Dispense 2 mL of REP Prep on the platen.

c. Remove the gel from the protective packaging and discard the overlay.

d. Using a REP Blotter C, gently blot the entire gel. Discard the blotter.

e. Place the left edge of the gel into the bottom of the cassette fitting the round hole over the upper pin and the obround hole over the lower pin. Gently lay the gel down over the REP Prep making sure no bubbles remain under the gel.

f. Place the top half of the Gel Cassette over the gel. Make sure the 2D barcode is located in the upper right corner of the cassette.

g. Place a Positive ID Barcode Label on the upper right hand side of the gel backing. Select the barcode that starts with the letter “G”.

E. Close the main door of the instrument.

**III. Automated Gel Electrophoresis**

A. Click the Start button on the menu bar. Select the **SPIFE** **Alkaline Hemoglobin 20 (Acid Blue)** test name from the drop down menu. Ensure the toggles for all Run Processes are set to “Yes” and click the Start Run button. The analyzer will load samples when appropriate, apply samples, electrophorese, stain, destain, dry and scan the gel. For details of Automated Gel Electrophoresis parameters, contact Technical Services.

B. After scanning, the Gel Cassette with the finished gel will be located in the scanner port on the front side of the instrument. If gel storage is required, remove and discard the two gel blocks.

C. After every test: discard the used blotters, Applicator Blades, Stain Cups and sample cups as biohazardous waste. Clean any residual stain from the electrophoresis platen, Gel Cassette and the Reagent Roller bar. For daily, weekly, and monthly maintenance reference the SPIFE Nexus Operator's Manual.

**Evaluation of the Hemoglobin Bands**   
**1. Qualitative evaluation:** The hemoglobin gels may be inspected visually for the presence of hemoglobin bands. The Helena Hemo Controls provide a marker for band identification. The hemoglobin gel should be inspected visually for the presence of abnormal hemoglobin bands.

**2. Quantitative evaluation:** The SPIFE Nexus Alkaline Hemoglobin Gel will automatically be scanned. An aperture size of 4 is recommended. Verify that the default setting for "Smoothing" is "No". "Autoslope" may be used with this test. **Stability of End Product:** The dried gels are stable for an indefinite period of time.  **Quality Control:** The control for hemoglobin electrophoresis is available from Helena Laboratories: AFSC Hemo Control (Cat. No. 5331). The control should be used as a marker for the location of particular hemoglobin bands. It may be quantitated for verification of the accuracy of the procedure. Refer to the package insert provided with the control for assay values and migration patterns. Use the control on each gel run.

**RESULTS**

Figure 1 illustrates the electrophoretic mobility of bands on the SPIFE Nexus Alkaline Hemoglobin Gel.



**LIMITATIONS**

Some abnormal hemoglobins have similar electrophoretic mobilities and must be differentiated by other methodologies. **Further testing required:**

1. Due to the high prevalence of HbF the sample may need to be redrawn in one or two weeks.

2. A second test method is necessary for confirmation of abnormal hemoglobins detected.

3. Low levels of HbF (1%-10%) and HbA2 may be accurately quantitated using any commercially available HbF or HbA2 method.

4. The relative migration of a hemoglobin variant is concentration dependent, with variants at a lower concentration (g/dL) migrating further from the application point.

**REFERENCE VALUES**

At birth, the majority of hemoglobin in the erythrocytes of the normal individual is fetal hemoglobin, HbF. Some of the major adult hemoglobin, HbA, and a small amount of HbA2 are also present. At the end of the first year of life and through adulthood, the major hemoglobin present is HbA with up to 3.7% HbA2 and less than 2% HbF.3 Age appropriate reference ranges need to be established by the end user.

**INTERPRETATION OF RESULTS**

Most hemoglobin variants cause no discernible clinical symptoms, so are of interest primarily to research scientists. Variants are clinically important when their presence leads to sickling disorders, thalassemia syndromes, life long cyanosis, hemolytic anemias, erythrocytosis or if the heterozygote is of sufficient prevalence to warrant genetic counseling. The combinations of HbSS, HbSD-Los Angeles and HbSO-Arab lead to serious sickling disorders.2 Several variants including HbH, E-Fort Worth and Lepore cause a thalassemic blood picture.2

The two variant hemoglobins of greatest importance in the U.S., in terms of frequency and pathology, are HbS and HbC.2 Sickle cell anemia (HbSS) is a lethal disease that first manifests itself at about 5 to 6 months of age. The clinical course presents agonizing episodes of pain and temperature elevations with anemia, listlessness, lethargy and infarct in virtually all organs of the body. The individual with homozygous HbCC suffers mild hemolytic anemia which is attributed to the precipitation or crystallization of HbC within the erythrocytes. Cases of HbSC disease are characterized by hemolytic anemia that is milder than sickle-cell anemia.

The thalassemias are a group of hemoglobin disorders characterized by hypochromia and microcytosis due to the diminished synthesis of one globin chain (the a or b) while synthesis of the other chain proceeds normally.10,11 This unbalanced synthesis results in unstable globin chains. These precipitate within the red cell, forming inclusion bodies that shorten the life span of the cell. In a-thalassemias the a-chains are diminished or absent, and in the b-thalassemia the b-chains are affected. Another quantitative disorder of hemoglobin synthesis, hereditary persistent fetal hemoglobin (HPFH), represents a genetic failure of the mechanisms that turn off gamma chain synthesis at about four months after birth which results in a continued high percentage of HbF. It is a more benign condition than the true thalassemias and persons homozygous for HPFH have normal development, are asymptomatic and have no anemia.11

The most common hemoglobin abnormalities:

Sickle Cell Trait   
This is a heterozygous state showing HbA and HbS and a normal amount of HbA2 under alkaline conditions. Results under acidic conditions agar show hemoglobins in the HbA and HbS migratory positions (zones).

Sickle Cell Anemia   
This is a homozygous state showing almost exclusively HbS, although a small amount of HbF may also be present.

Sickle-C Disease   
This is a heterozygous state demonstrating HbS and HbC.

Sickle Cell-Thalassemia Disease

This condition shows HbA, HbF, HbS and HbA2.

In Sickle Cell b°-Thalassemia HbA is absent.   
In Sickle Cell b+-Thalassemia HbA is present in reduced quantities.

Thalassemia-C Disease

This condition shows HbA, HbF and HbC.

C Disease   
This is a homozygous state showing almost exclusively HbC.

Thalassemia Major

This condition shows HbF, HbA and HbA2.

**SPECIFIC PERFORMANCE CHARACTERISTICS**

**PRECISION**

Reproducibility was assessed over a 5 day period. Four hemoglobin samples were tested on two gels per day on three SPIFE Nexus instruments. Sixty to ninety determinations per hemoglobin fraction in total were collected depending on the hemoglobin sample.

**HbA Within Day Between Day Between Instrument Total**

**Sample N Mean % SD CV% SD CV% SD CV% SD CV%**

1 90 96.7 0.80 0.83 0.18 0.19 0.81 0.84 0.82 0.85

2 60 41.0 2.98 7.27 1.36 3.31 3.27 7.98 3.35 8.18

3 60 59.4 1.38 2.33 0.27 0.45 1.41 2.37 1.45 2.44

4 60 57.4 2.08 3.63 0.46 0.80 2.13 3.71 2.18 3.79

**HbF Within Day Between Day Between Instrument Total**

**Sample N Mean % SD CV% SD CV% SD CV% SD CV%**

2 60 59.0 2.95 5.00 1.39 2.35 3.26 5.52 3.33 5.64

4 60 17.6 1.40 7.96 0.23 1.30 1.42 8.07 1.42 8.07

**HbS Within Day Between Day Between Instrument Total**

**Sample N Mean % SD CV% SD CV% SD CV% SD CV%**

3 60 37.6 1.22 3.24 0.23 0.61 1.24 3.29 1.26 3.36

4 60 16.3 1.02 6.23 0.10 0.64 1.02 6.26 1.04 6.36

**HbA2 Within Day Between Day Between Instrument Total**

**Sample N Mean % SD CV% SD CV% SD CV% SD CV%**

1 90 33.3 7.96 23.9 1.87 5.61 8.16 24.51 8.16 24.51

3 60 3.0 0.50 16.69 0.50 16.69 0.50 16.82 0.51 16.84

**HbC Within Day Between Day Between Instrument Total**

**Sample N Mean % SD CV% SD CV% SD CV% SD CV%**

4 60 8.7 0.79 9.04 0.16 1.80 0.80 9.22 0.81 9.30

**CORRELATION**

15 hemoglobin samples (normal and abnormal) were run using the SPIFE Alkaline Hemoglobin method on both the SPIFE Touch and SPIFE Nexus with the following correlation:

n = 15

Y = 0.901X – 3.580

R = 0.991

X = SPIFE Alkaline Hemoglobin on SPIFE Touch

Y = SPIFE Alkaline Hemoglobin on SPIFE Nexus

**BIBLIOGRAPHY**

1. Wintrobe, Maxwell M., Clinical Hematology, 6th Edition, LeFebiger, Philadelphia, 1967.

2. Fairbanks, V.F., Diagnostic Medicine, Nov/Dec., 53-58, 1980.

3. Tietz, N.W., Clinical Guide to Laboratory Tests, 4th Edition, W.B. Saunders Co. Philadelphia, 2006.

4. Schneider, R.G., et al., Laboratory Identification of the Hemoglobins, Lab Management, August, 29-43, 1981.

5. Center for Disease Control, Laboratory Methods for Detecting Hemoglobinopathies, U.S. Department of Health and Human Services/Public Health Service, 1984.

6. Schneider, R.G., Methods for Detection of Hemoglobin Variants and Hemoglobinopathies in the Routine Clinical Laboratory, CRC Critical Reviews in Clinical Laboratory Sciences, 1978.

7. Schneider, R.G., et al., Abnormal Hemoglobins in a Quarter Million People, Blood, 48(5):629-637, 1976.

8. Huisman, T.H.J. and Schroeder, W.A., New Aspects of the Structure, Function, and Synthesis of Hemoglobins, CRC Press, Cleveland, 1971.

9. Schmidt, R.M., et al, The Detection of Hemoglobinopathies, CRC Press, Cleveland 1974.

10. Weatherall, D.J. and Clegg, J.B., The Thalassaemia Syndromes, Blackwell Scientific Publications, Oxford, 1972.

11. Lehman, H. and Huntsman, R.G., Man’s Haemoglobins, J.B. Lippincott Co., Philadelphia, 1974.

For Sales, Technical and Order Information and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena’s liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer’s exclusive remedies.

In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.

Pro. 273

11/22

